Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol

NCT03216525 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT03216525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03216525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2018
Completion date
June 1, 2024
Enrollment
136 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer